Lopirel 75 mg (Tablet)
Unit Price: ৳ 12.00 (3 x 10: ৳ 360.00)
Strip Price: ৳ 120.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Clopidogrel bisulphate |
| Company | Incepta pharmaceuticals ltd |
Indications
- Reduce rate of myocardial infarction (MI)
- Reduce rate of stroke in patients with non-ST-segment elevation ACS
- Reduce rate of stroke in patients with acute ST-elevation myocardial infarction (STEMI)
- Reduce rate of MI and stroke in patients with established peripheral arterial disease
- Usable for patients with recent MI, recent stroke, or established peripheral arterial disease
Pharmacology
- Clopidogrel is a prodrug
- Inhibits platelet activation and aggregation
- Irreversible binding of active metabolite to P2Y12 class of ADP receptors on platelets
- Dose-dependent inhibition of platelet aggregation
Dosage & Administration
- 300 mg oral loading dose for acute coronary syndrome
- 75 mg once daily orally for recent MI, recent stroke, or established peripheral arterial disease
- Oral administration with or without food
Interaction
- Increases risk of bleeding when used with NSAIDs, warfarin, SSRIs, or SNRIs
- Avoid concomitant use with CYP2C19 inhibitors (omeprazole or esomeprazole)
- Increases plasma concentrations of Repaglinide when used with it
Contraindications
- Hypersensitivity to the drug substance or any component
- Active pathological bleeding such as peptic ulcer or intracranial hemorrhage
Side Effects
- Common: Bleeding, Diarrhoea, gastrointestinal discomfort, haemorrhage, Skin reactions
- Rare: Acquired haemophilia, anaemia, angioedema, arthralgia, arthritis, bone marrow disorders
Pregnancy & Lactation
- Usage during pregnancy only if clearly needed
- Unknown excretion of clopidogrel in human breast milk
Precautions & Warnings
- Metabolism impairment due to genetic variations in CYP2C19
- Reduced antiplatelet activity when used with CYP2C19 inhibitors or in poor metabolizer
- Increased risk of bleeding due to inhibition of platelet aggregation for the lifetime of platelet
- Risk of cardiovascular events upon discontinuation
- Thrombotic Thrombocytopenic Purpura (TTP) reported
- Hypersensitivity reported in some patients
Use in Special Populations
- Safety and effectiveness not established in pediatric populations
- No dosage adjustment necessary in elderly patients
Overdose Effects
- May lead to bleeding complications
- Platelet transfusion may restore clotting ability
Therapeutic Class
- Anti-platelet drugs
Storage Conditions
- Keep below 30°C temperature in a dry place
- Protected from light
- Do not freeze
- Keep out of the reach of children